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ABSTRACT 38 
Carbapenem-resistant Enterobacteriaceae are an urgent threat to global human health. These 39 
organisms produce β-lactamases with carbapenemase activity, such as the metallo-β-40 
lactamase NDM-1, which is notable due to its association with mobile genetic elements and 41 
the lack of a clinically useful inhibitor. Here we examined the ability of copper to inhibit the 42 
activity of NDM-1 and explored the potential of a copper coordination complex as a 43 
mechanism to efficiently deliver copper as an adjuvant in clinical therapeutics. An NDM-44 
positive Escherichia coli isolate, MS6192, was cultured from the urine of a patient with 45 
urinary tract infection. MS6192 was resistant to antibiotics from multiple classes, including 46 
diverse -lactams (penicillins, cephalosporins, and carbapenems), aminoglycosides and 47 
fluoroquinolones. However, in the presence of copper (range 0-2 mM), the susceptibility of 48 
MS6192 to the carbapenems ertapenem and meropenem increased significantly. In standard 49 
checkerboard assays, copper decreased the MIC of ertapenem and meropenem against 50 
MS6192 in a dose-dependent manner, suggesting a synergistic mode of action. To examine 51 
the inhibitory effect of copper in the absence of other β-lactamases, the blaNDM-1 gene from 52 
MS6192 was cloned and expressed in a recombinant E. coli K-12 strain. Analysis of cell-free 53 
extracts prepared from this strain revealed copper directly inhibits NDM-1 activity, and this 54 
was further confirmed using purified recombinant NDM-1. Finally, delivery of copper at a 55 
low concentration of 10 μM using the FDA-approved coordination complex copper-56 
pyrithione sensitised MS6192 to ertapenem and meropenem in a synergistic manner. Overall, 57 
this work demonstrates the potential use of copper-coordination complexes as novel 58 
carbapenemase adjuvants.  59 
60 
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INTRODUCTION  61 
Carbapenems (ertapenem, doripenem, imipenem, meropenem) are β-lactam antibiotics with 62 
broad-spectrum activity (1, 2). They are generally used as a last resort for treating infections 63 
caused by cephalosporin-resistant Enterobacteriaceae. Hence, it is alarming that resistance to 64 
carbapenems, primarily in Gram-negative bacteria, has now emerged and disseminated 65 
worldwide, leading to high rates of treatment failure and increased complications (3-6). 66 
Carbapenem-resistant Enterobacteriaceae (CRE), which include Escherichia coli and 67 
Klebsiella pneumoniae, are frequently associated with hospital-acquired lung, urinary tract, 68 
bloodstream, and device-related infections, with urinary tract infections (UTI), including 69 
catheter-associated UTI, being the most common infection acquired in the nosocomial setting 70 
(7). Combined with the asymptomatic carriage of CRE (8, 9) and the potential for 71 
transmission of resistance via mobile genetic elements (10, 11), it is not surprising that CRE 72 
are recognised as one of the most urgent threats to global human health today (12).  73 
 74 
Mechanisms of carbapenem resistance in CRE frequently involve the expression of 75 
carbapenemases, which are broad-spectrum β-lactamases that hydrolyse carbapenems with 76 
high catalytic efficiency. These carbapenemases are diverse and include the Ambler class A 77 
(e.g. KPC) and class D (e.g. OXA-48) serine hydrolases, as well as class B metallo-β-78 
lactamases (MBLs, e.g. VIM, IMP, NDM) (13). One approach to combat carbapenem 79 
resistance would be to develop adjuvants that inhibit carbapenemases, thus restoring 80 
susceptibility to carbapenems and ultimately extending the use of these antibiotics. For the 81 
serine-dependent lactamases, this strategy is best exemplified by the use clavulanic acid and 82 
tazobactam in the clinic as β-lactam adjuvants that inhibit the activity of extended-spectrum 83 
β-lactamases (ESBLs) and restore susceptibility of ESBL-positive strains to β-lactams (14). 84 
However, such inhibitors are ineffective against MBLs (15, 16). MBLs require up to two zinc 85 
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ions for their activity and thus are inhibited by reagents that disrupt zinc binding, either by 86 
complete chelation (e.g. EDTA) or partial coordination (e.g. thiol-containing compounds) 87 
(14, 15, 17). Despite their effectiveness in vitro, these inhibitors have not proven to be 88 
clinically useful (14, 15).   89 
   90 
Here we present evidence for a possible approach to inactivate MBLs with copper ions. 91 
Using the New Delhi Metallo--lactamase 1 (NDM-1) enzyme as our model, we show that 92 
copper ions inhibit the activity of this MBL in vitro and enhance the susceptibility of NDM-93 
positive isolates of E. coli to carbapenems. Using pyrithione, an FDA-approved antifungal 94 
agent that exerts an antimicrobial effect by acting as a copper delivery molecule (18), we also 95 
provide proof of concept that copper coordination complexes have the potential to be used as 96 
carbapenem adjuvants in the clinic.  97 
 98 
MATERIALS AND METHODS 99 
Bacterial strains, reagents, and culture conditions. E. coli MS6192 is an NDM-1-positive 100 
strain isolated from the urine of a patient with UTI. E. coli MG1655 is a K-12 strain and is 101 
susceptible to all antibiotics. All strains were propagated from frozen glycerol stocks on 102 
Luria-Bertani (LB) agar at 37 °C. Liquid cultures were prepared in LB broth and grown at 37 103 
°C with shaking at 200 rpm. Antibiotic discs (Sensi-discs) were purchased from BD 104 
Biosciences (Australia). Copper(II) sulfate (C8027), zinc(II) pyrithione (H6377), ertapenem 105 
sodium (SML1238), and meropenem trihydrate (M2574) were purchased from Sigma 106 
(Australia). Stocks of reagents were prepared in deionised water except zinc pyrithione, 107 
which was dissolved in DMSO. Copper(II) pyrithione was prepared by adding equimolar 108 
amounts of copper sulfate to a solution of zinc(II) pyrithione.  109 
  110 
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Cloning and expression of the blaNDM-1 gene in MG1655. The blaNDM-1 gene from MS6192 111 
was amplified with primers 7414 (5'-tgataaggatccattcagctttcacccattgg) and 7415 (5'-112 
tcgaaaaagcttgatggcagattgggggtga) and cloned between the BamHI and HindIII sites of 113 
pSU2718. The resulting plasmid pSU2718::blaNDM-1 was transformed into E. coli MG1655 114 
by electroporation to generate the NDM-1-positive strain MS8485. MS8485 was cultured in 115 
the presence of chloramphenicol (30 µg/mL) and IPTG (0.1 mM) to maintain the plasmid and 116 
promote expression of NDM-1, respectively.  117 
 118 
Antibiotic susceptibility assays. The antimicrobial susceptibility profile of MS6192 was 119 
determined using the Vitek 2 automated AST-N426 card (bioMérieux). The E-test was used 120 
to determine MICs for meropenem, imipenem and ertapenem. Disc diffusion assays were 121 
performed by seeding LB agar containing copper sulfate (0-2 mM) or copper pyrithione (0-20 122 
µM) with bacterial suspensions at an OD600 of 0.18 (~1.5 x 108 CFU/mL, equivalent to 0.5 123 
McFarland standard). Zones of clearance around antibiotic discs were measured after 124 
incubation at 37 °C for 24 h. Checkerboard assays were also performed in LB. Bacterial 125 
suspensions were prepared to an OD600 of 0.001 (ca. 5 x 105 CFU/mL) and exactly 100 µL 126 
was dispensed into each well of a U-bottomed 96-well microtiter plate. To each well were 127 
also added 50 µL of LB broth containing ertapenem or meropenem (0-64 µg/mL) and 50 µL 128 
of LB broth containing copper sulfate (0-5 mM) or copper pyrithione (0-20 µM). Turbidity in 129 
each well was measured using a microtiter plate reader after incubation at 37 °C for 24 h. The 130 
minimum inhibitory concentration (MIC) was defined as the lowest concentration of agent 131 
that completely inhibited bacterial growth. The fractional inhibitory concentration (FIC) for 132 
each agent was defined as its MIC in combination divided by its MIC alone. The FIC index 133 
was the sum of the FIC values for both agents. 134 
 135 
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Overexpression and purification of recombinant NDM-1. To obtain the pure NDM-1 136 
enzyme, the coding sequence for NDM-1 (residues 27-270) was amplified from strain 137 
MS6192 using primers 7456 (5’-TACTTCCAATCCAATGCGATGCCCGGTGAAATCC-138 
3’) and 7457 (5’-TTATCCACTTCCAATGTCAGCGCAGCTTGTCG-3’) containing 139 
ligation-independent cloning (LIC) overhangs. The gene product was cloned into pAL vector 140 
encoding a N-terminal His6-tag followed by a thioredoxin (TRX) domain and a TEV protease 141 
cleavage site. NDM-1 was expressed overnight at 37 oC in E. coli BL21 (DE3) host in the 142 
presence of 0.5 mM IPTG. Cells were lysed in 25 mM Tris-Cl buffer (pH 7.5, 150 mM NaCl, 143 
20 μM ZnCl2) by sonication and NDM-1 protein was purified on a Ni-NTA HisTrap column 144 
(GE Healthcare) using the same buffer and a gradient of 0-400 mM imidazole. The N-145 
terminal His6-tag was cleaved with TEV protease and re-purified by elution from a Ni-NTA 146 
HisTrap column.  147 
 148 
Assays of NDM-1 activity. To prepare cell-free extracts, bacteria (50 mL) were cultured 149 
without or with copper sulfate (2 mM) to the mid-exponential phase (OD600 ~ 0.4-0.5), 150 
centrifuged (5000 g, 10 min), washed with PBS, resuspended in 500 µL of HEPES buffer (50 151 
mM, pH 7.4), lysed by sonication (5 × 10 s bursts at 10 W each), and clarified by 152 
centrifugation (20,000 g, 5 min). -lactamase activity in these cell-free extracts was measured 153 
by following the hydrolysis of nitrocefin (0-250 µM) in HEPES buffer (50 mM, pH 7.4) at 35 154 
°C. Copper sulfate (0-100 µM) was added into the nitrocefin solution immediately before 155 
addition of the cell-free extracts to initiate hydrolysis. Absorbance values at 485 nm (, 17.5 156 
mM-1 cm-1) were monitored continuously for 2 min in a spectrophotometer. Initial rates (up to 157 
30 s) were normalised to total protein concentration as determined by BCA assay. Data were 158 
fitted to the Michaelis-Menten equation that incorporates terms describing either 159 
noncompetitive or competitive inhibition using the software package Prism 7 (GraphPad).  160 
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 161 
RESULTS 162 
Copper ions potentiate the antibacterial activity of carbapenems against NDM-positive 163 
E. coli. MS6192 is an NDM-positive, carbapenem-resistant isolate of E. coli that is also 164 
resistant to cephalosporins, fluoroquinolones and aminoglycosides (Table 1). To assess the 165 
effect of copper ions on this antibiotic resistance profile, we first employed a modified disc 166 
diffusion assay on solid media containing copper sulfate (0-2 mM). At these concentrations, 167 
copper alone did not inhibit the growth of MS6192 but it led to dose-dependent increases in 168 
the zones of clearance around carbapenem discs (ertapenem and meropenem) (Table 2). This 169 
potentiating effect of copper was also observed in 11 additional NDM-positive clinical 170 
isolates (Table S1 in Supplemental Material) but only strain MS6192 was selected for further 171 
study. The zones of clearance around other antibiotic discs, including other β-lactams, 172 
remained unchanged (Table 2), suggesting that the potentiating effect of copper was specific 173 
to carbapenems. Standard checkerboard assays further confirmed that addition of copper 174 
decreased the MIC of carbapenems against strain MS6192 in a dose-dependent manner 175 
(Figure 1A). The FIC indices were 0.17 ± 0.13 for the combinations of copper and 176 
ertapenem, and 0.11 ± 0.06 for copper and meropenem, suggesting that the interaction 177 
between copper and carbapenems was synergistic (FIC < 0.5) (Figure S1A).  178 
 179 
Copper ions inhibit the activity of NDM-1 carbapenemase. Excess copper ions are known 180 
to inactivate a variety of metalloenzymes (19-22). Because the observed potentiating effect of 181 
copper was specific to carbapenems (Table 2), we hypothesised that this metal impacted the 182 
activity of NDM-1. To test this idea, strain MS6192 was cultured without and with copper 183 
sulfate (2 mM) to mid-exponential phase and total -lactamase activities in cell-free extracts 184 
were measured using nitrocefin as the substrate. As predicted, growth in copper-rich medium 185 
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led to a decrease in lactamase activity in MS6192 (Figure 2A). However, only a partial 186 
reduction was achieved (ca. 50%, Figure 2A), likely because MS6192 possesses multiple 187 
β-lactamase enzymes (NDM-1, CTX-M-15, OXA-1), some of which are not MBLs and thus 188 
may be insensitive to copper. 189 
 190 
To simplify this analysis, we cloned the blaNDM-1 gene of MS6192 under an IPTG-inducible 191 
promoter and transformed the resulting plasmid (pSU2718::blaNDM-1) into the K-12 strain 192 
MG1655. The resulting NDM-positive recombinant strain MS8485 was resistant to penicillin, 193 
cephalosporins and carbapenems (Figure 3), as expected from the broad-spectrum activity of 194 
NDM-1. Disc diffusion and checkerboard assays confirmed that addition of copper to the 195 
culture medium restored the susceptibility of MS8485 to all β-lactams to levels that were 196 
comparable to MG1655 (Figure 1 and Figure 3). The mode of action was again synergistic 197 
with FIC indices of 0.11 ± 0.03 for ertapenem and 0.11 ± 0.04 for meropenem (Figure S1B). 198 
These results were consistent with a loss of NDM-1 activity in the presence of copper. 199 
Indeed, extracts of copper-treated MS8485 did not display appreciable NDM-1 activity when 200 
tested using nitrocefin as the substrate (Figure 2B).  201 
 202 
As a control, we measured the production of NDM-1 in MS8485 by immunoblot analysis. 203 
Expression of the blaNDM-1 gene in strain MS8485 is induced by IPTG but to our surprise, 204 
copper treatment led to a reduction in the amount of NDM-1 enzyme (Figure S2). This may 205 
account, at least partially, for the loss of -lactamase activity in copper-treated cells (Figure 206 
2B). Similar observations were made using strain MS6192 (Figure S2 and Figure 2A), but the 207 
blaNDM-1 gene in this strain is expressed from its native promoter. It is possible that copper 208 
exerts an effect at the step of enzyme folding, maturation, or secretion.  209 
         210 
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Although we observed the production (albeit reduced) of NDM-1 in copper-containing 211 
MS8485 cultures, we did not detect appreciable NDM-1 activity above background level 212 
(Figure 2B). Thus, we tested the possibility that copper also directly inhibited the activity of 213 
NDM-1 by measuring the kinetic properties of this MBL in cell-free extracts of MS8485 214 
prepared following culture in copper-free medium. Addition of copper (0-80 µM) to the 215 
reaction buffer led to a dose-dependent decrease in NDM-1 activity (Figure 4A). The data 216 
were best fitted to a noncompetitive model of inhibition (R2 = 0.97) with an apparent 217 
inhibition constant (Ki) of 47 ± 5 µM in these cell-free extracts (Figure 4A and Figure S3A). 218 
A noncompetitive mode of inhibition was confirmed by repeating these measurements using 219 
purified recombinant NDM-1 (Figure 4B and Figure S3B). A lower Ki of 3.7 ± 0.3 µM (R2 = 220 
0.99) was obtained, confirming that copper strongly inhibits NDM-1 activity. A 221 
noncompetitive mode of inhibition by Cu(II) with similar magnitude was recently reported 222 
for the MBL AIM-1 (23).  223 
 224 
Susceptibility of NDM-positive E. coli to carbapenems is enhanced using a copper 225 
coordination complex. Ionic copper salts are lipid-insoluble and so are poorly membrane-226 
permeable. As a consequence, high doses are often required to achieve an antibacterial effect 227 
in vitro (e.g. > 2 mM copper sulfate in our assays), hampering the development of copper-228 
based antibiotics in clinical medicine. We and others have used small (<500 Da) and 229 
lipophilic compounds with high binding affinities to copper to act as membrane-permeable 230 
carriers of copper ions (24-26). These copper coordination complexes are under investigation 231 
as clinical therapeutics (27-29) and some are potent antibacterial agents, at least in vitro (24-232 
26). One such carrier, pyrithione (Figure 5A), has been marketed for decades as an antifungal 233 
agent in healthcare and consumer products. Pyrithione is usually supplied in a zinc-234 
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coordinated form but its action relies on trans-metallation by trace exogenous copper ions and 235 
subsequent delivery of antimicrobial copper (18). 236 
   237 
To determine if pyrithione can deliver copper ions to CRE and inhibit NDM-1 238 
carbapenemase activity, we repeated our checkerboard assays in the presence of copper-239 
loaded pyrithione (0-20 µM). As anticipated, the copper-pyrithione complex increased the 240 
susceptibility of MS6192 and MS8485 to ertapenem and meropenem (Figure 5B and Figure 241 
5C). The FIC indices were 0.18 ± 0.07 (ertapenem) and 0.13 ± 0.05 (meropenem) for 242 
MS6192, and 0.28 ± 0.11 (ertapenem) and 0.17 ± 0.08 (meropenem) for MS8485 (Figure S4), 243 
again suggesting that the mode of interaction was synergistic. Copper was required for this 244 
synergy, as zinc-loaded pyrithione had little effect on carbapenem resistance (Figure 5B and 245 
Figure 5C). It must be noted that, in contrast to copper ions (Figure 1), copper-pyrithione did 246 
not decrease the MIC values of carbapenems against MS8485 to MG1655 levels (Figure 5). 247 
At 20 µM, copper-pyrithione completely suppressed growth of E. coli even in the absence of 248 
carbapenems (Figure 5B and Figure 5C). Therefore, the potentiating effect of copper-249 
pyrithione is a combination of its direct antibacterial action and the inhibition of 250 
carbapenemase activity.  251 
 252 
DISCUSSION 253 
The antibacterial properties of copper have been recognized for millenia and in the pre-254 
antibiotic age, simple ionic salts and complexes of copper were used to control bacterial 255 
infections (30). It is now established that excess copper ions poison bacterial cells by 256 
inactivating key metalloenzymes, particularly those containing solvent-accessible iron (19) 257 
and zinc (20). This is a consequence of the high relative affinity of copper to these metal-258 
binding sites, which leads to metal exchange and displacement of the cognate but weaker 259 
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binding metals (21). Here we showed that copper ions (as Cu(II)) can directly inactivate the 260 
metalloenzyme NDM-1. The precise mechanism remains to be elucidated but we propose that 261 
copper may disrupt binding of one or both of the zinc ions in the active site of NDM-1, in 262 
agreement with a recent study with the MBL AIM-1, which demonstrated that two Cu(II) 263 
ions bind to the enzyme in close vicinity (23). Alternatively, copper ions may bind to an 264 
allosteric site outside the zinc-containing pocket. Both scenarios (summarised in Figure 6) 265 
would be consistent with the observed noncompetitive mode of enzyme inhibition but 266 
detailed structural and biochemical studies of the purified enzyme will be required to describe 267 
the molecular basis of this inhibition.  268 
 269 
Our immunoblot results indicated that copper may also affect the synthesis, maturation 270 
(enzyme folding and zinc site assembly), or stability of NDM-1. This MBL is anchored to the 271 
outer membrane and secreted in outer membrane vesicles (31). However, NDM-1 is folded 272 
and metallated in the periplasm (32). These processes are universal to all MBLs, including 273 
the VIM, IMP and AIM carbapenemases, and they can also be disrupted by excess copper 274 
(23, 33, 34). Indeed, a recent study has suggested that NDM-1 enzymes lacking the zinc 275 
centres are degraded in the cell (31).  276 
 277 
In our experiments, copper was supplied in the growth medium as Cu(II) ions. Inactivation of 278 
NDM-1 via the various potential routes as described above would rely on diffusion of these 279 
Cu(II) ions into the periplasm. However, the concentration of copper required to restore 280 
susceptibility of MS6192 to carbapenems (~2 mM) in our study was high and unlikely to be 281 
tolerated physiologically. We were able to reduce this amount by two orders of magnitude to 282 
10 µM by coordinating the copper ion to pyrithione, an FDA-approved antifungal agent that 283 
acts as a membrane-permeable carrier of copper. Pyrithione and its zinc-coordinated form are 284 
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currently approved for topical administration. While most formulations in consumer goods 285 
and healthcare products contain up to 2% of this compound, it is unknown whether the 286 
copper form is equally tolerated. However, a variety of other copper carriers are currently 287 
being investigated for their therapeutic potential (24-26). The results presented here provide 288 
an early proof-of-concept that a ligand or carrier-mediated delivery of copper ions to the 289 
bacterial cell, in this case to target NDM-1 carbapenemase activity, is possible. Our data also 290 
add to an emerging role of metal ions in enhancing the action of antibiotics. For example, 291 
silver can potentiate vancomycin activity by disrupting multiple bacterial cellular processes, 292 
including disulfide bond formation, metabolism, and iron homeostasis (35). 293 
 294 
The ability of copper to inhibit NDM-1 carbapenemase activity also provides an opportunity 295 
to develop therapeutics that work in concert with the host innate immune system. Although 296 
the availability and location of copper in the human body are tightly regulated, copper is 297 
mobilized in response to inflammation, leading to increased copper concentrations at the site 298 
of infection. For instance, mobilization of copper occurs in infected macrophages (36). 299 
Infection by a variety of pathogens also results in increased copper levels in the serum, liver, 300 
and spleen of animals (37, 38). In the case of E. coli, particularly uropathogenic strains, it has 301 
been shown that copper levels are elevated (to ~ 0.3 µM) in the urine of patients with UTI 302 
compared to healthy controls (39, 40). Thus, delivery of membrane-permeable copper carriers 303 
such as pyrithione into the urinary tract may allow us to exploit this host-derived copper and 304 
enhance its action against CRE.  305 
 306 
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 438 
Table 1. Antibiotic resistance profile of E. coli strain MS6192. 439 
 440 
Antibiotic MIC  
(µg/mL) Class Name 
- 
lactams 
Penicillins 
Ampicillin ≥ 32 
Amoxicillin/Clavulanic acid ≥ 32 
Ticarcillin/Clavulanic acid ≥ 128 
Piperacillin/Tazobactam ≥ 128 
Cephalo- 
sporins 
1st Cefazolin ≥ 64 
2nd Cefotixin ≥ 64 
3rd Ceftazidime ≥ 64 
3rd Ceftriaxone ≥ 64 
4th Cefepime ≥ 64 
Carbapenems Meropenem ≥ 16 
Aminoglycosides 
Amikacin ≥ 64 
Gentamicin ≥ 16 
Tobramycin ≥ 16 
Fluoroquinolones Norfloxacin ≥ 16 Ciprofloxacin ≥ 4 
Others 
Nitrofurantoin 128 
Trimethoprim ≥ 16 
Trimethoprim/Sulfamethoxazole ≥ 32 
 441 
 442 
 443 
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 445 
Table 2. Effect of copper ions on the resistance of E. coli MS6192 to antibiotics as 446 
determined by disc diffusion assays.  447 
 448 
Antibiotics Zone of clearance (Diameter, mm)a 
Class Name Amount (µg) 
[copper sulfate] (mM) 
0 1 2 
β- 
lactams 
Carba- 
penems 
Ertapenem 10 8 11 26 
Meropenem 10 11 17 32 
Penicillins Ampicillin 10 < 7 < 7 < 7 
Cephalo- 
sporins 
Ceftriaxone 30 < 7 < 7 < 7 
Cefotaxime 30 < 7 < 7 < 7 
Monobactams Aztreonam 30 < 7 < 7 < 7 
Aminoglycosides Gentamicin 10 < 7 < 7 < 7 Tobramycin 10 < 7 < 7 < 7 
Fluoroquinolones Ciprofloxacin 5 < 7 < 7 < 7 
aValues are representative of three independent experiments. The diameter of the disc was 7 449 
mm and a value of < 7 mm indicated that no zone of clearance around was observed around 450 
the disc. 451 
 452 
 453 
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FIGURE LEGENDS 455 
 456 
Figure 1. Effects of sub-inhibitory amounts of copper ions (0 – 2.5 mM) on the MIC values 457 
of ertapenem (top panels) and meropenem (bottom panels) against E. coli strains (A) 458 
MS6192, (B) MS8485, and (C) MG1655 as determined by standard checkerboard assays. 459 
Data shown were from three independent replicates. An MIC value of 0 µg/mL indicated that 460 
growth was inhibited in the absence of the carbapenem. 461 
 462 
Figure 2. -lactamase activity in E. coli strains (A) MS6192 and 463 
(B) MS8485. Bacteria were cultured without (-Cu) and with sub-inhibitory amounts of 464 
copper (2 mM, +Cu) to the mid-exponential phase and lysed by sonication. As a negative 465 
control, MG1655 was also cultured without any copper (Control). Lactamase activities were 466 
measured in cell-free extracts and averaged from three independent replicates. Error bars 467 
represent ± SD. 468 
 469 
Figure 3. Effect of sub-inhibitory amounts of copper ions (0–2 mM) on the resistance of E. 470 
coli strains (A) MG1655 (black bars) and (B) -lactam antibiotics as 471 
determined by disk diffusion assays. Diameters of the zones of clearance were averaged from 472 
three independent replicates. Error bars represent ± SD. The diameter of the disk was 7 mm 473 
and a value of < 7 mm indicated that no zone of clearance around was observed around the 474 
disc. 475 
 476 
Figure 4. Direct inhibitory effects of copper ions on NDM-1 activity. Enzyme activity in (A) 477 
cell-free extracts of MS8485 or (B) purified NDM-1 from MS6192 was measured in the 478 
presence of copper sulfate using nitrocefin as substrate. The concentrations of copper sulfate 479 
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in micromolar were indicated to the right of each curve. Each data point was averaged from 480 
three independent replicates. Error bars represent ± SEM. Data were fitted to noncompetitive 481 
(solid lines) and competitive models of enzyme inhibition (Figure S3). 482 
 483 
Figure 5. Structure of copper-pyrithione complex (A) and the effects of sub-inhibitory 484 
amounts of copper-pyrithione (0–20 µM, solid lines) and zinc-pyrithione (0–20 µM, dotted 485 
lines) on the MIC values of ertapenem (B) and meropenem (C) against E. coli strains 486 
MS6192, MS8485, and MG1655 as determined by standard checkerboard assays. Data shown 487 
were from three independent replicates. An MIC value of 0 µg/mL indicates that growth was 488 
inhibited in the absence of added carbapenem. 489 
 490 
Figure 6. General schematic of the effect of copper ions on NDM-1 activity. Our data 491 
indicates that copper can directly inhibit the carbapenemase activity of NDM-1, and that it 492 
may also may also affect NDM-1 synthesis, maturation, or stability. Cu(II), and Zn(II) ions 493 
are depicted by black circles and light grey circles, respectively. IM, inner membrane. OM, 494 
outer membrane. OMV, outer membrane vesicle. 495 
 496 
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